Skip to main content

Advertisement

SpringerLink
Log in

Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing

  • CE - Cochrane's Corner
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev, CD006162

  2. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397

    Article  PubMed  CAS  Google Scholar 

  3. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775

    Article  PubMed  CAS  Google Scholar 

  4. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660–1672

    Article  PubMed  CAS  Google Scholar 

  5. Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134

    Article  PubMed  CAS  Google Scholar 

  6. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med 4:e184

    Article  PubMed  CAS  Google Scholar 

  7. Djulbegovic B et al (2000) The uncertainty principle and industry-sponsored research. Lancet 356:635–638

    Article  PubMed  CAS  Google Scholar 

  8. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173

    Article  PubMed  Google Scholar 

  9. NHI Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm

  10. EMEA (2006) Guideline on clinical investigation of medicinal product used in weight control. http://www.emea.europa.eu/pdfs/human/ewp/028196en.pdf

  11. Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194–1199

    Article  PubMed  CAS  Google Scholar 

  12. EMEA European Public Assessment Report (EPAR). http://www.emea.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm. Last accessed Jan 2007

  13. CRESCENDO Trial. http://clinicaltrials.gov/show/NCT00263042

  14. Reaven GM, Chen YD (1988) Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4:639–652

    Article  PubMed  CAS  Google Scholar 

  15. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428

    Article  PubMed  CAS  Google Scholar 

  16. Gale EA (2005) The myth of the metabolic syndrome. Diabetologia 48:1679–1683

    Article  PubMed  Google Scholar 

  17. Heath I (2006) Combating disease mongering: daunting but nonetheless essential. PLoS Med 3:e146

    Article  PubMed  Google Scholar 

  18. Moynihan R, Henry D (2006) The fight against disease mongering: generating knowledge for action. PLoS Med 3:e191

    Article  PubMed  Google Scholar 

  19. Mintzes B (2006) Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3:e198

    Article  PubMed  Google Scholar 

  20. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–28

    Article  PubMed  CAS  Google Scholar 

  21. Zimmet PZ, Alberti G (2005) Medscape diabetes & endocrinology. 7(2). Available at http://www.medscape.com/viewarticle/514211. Accessed on January 31, 2008

  22. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 370:1706–1713

    Article  PubMed  CAS  Google Scholar 

  23. Moynihan R, Heath I, Henry D (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324:886–891

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Italian Cochrane Centre, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157, Milan, Italy

    Rita Banzi, Lorenzo Moja, Ivan Moschetti & Alessandro Liberati

  2. Department of Critical Care Medicine and Surgery, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Gian Franco Gensini

  3. DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Roberto Gusinu

  4. Department of Critical Care Medicine and Surgery, University of Florence and Don Carlo Gnocchi Foundation IRCCS, Florence, Italy

    Andrea A. Conti

Authors
  1. Rita Banzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Moja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan Moschetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Liberati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gian Franco Gensini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Gusinu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea A. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Moja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Banzi, R., Moja, L., Moschetti, I. et al. Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing. Intern Emerg Med 3, 53–56 (2008). https://doi.org/10.1007/s11739-008-0139-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-008-0139-x

Search

Navigation